Thiopurine therapy in inflammatory bowel disease patients: Analyses of two 8-year intercept cohorts

Inflammatory Bowel Diseases

Volumn 16, Issue 9, 2010, Pages 1541-1549

  Jharap, B ^a   Seinen, M L ^a   De Boer, N K H ^a   Van Ginkel, J R ^a   Linskens, R K ^b   Kneppelhout, J C ^b   Mulder, C J J ^a   Van Bodegraven, A A ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Sint Anna Hospital   (Netherlands)

Author keywords

6 mercaptopurine; Adverse events; Azathioprine; Effectiveness; Inflammatory bowel disease

Indexed keywords

6 METHYLTHIOINOSINE; AZATHIOPRINE; INFLIXIMAB; MERCAPTOPURINE; TIOGUANINE;

ADOLESCENT; ADULT; AGED; ARTHRALGIA; ARTICLE; BONE MARROW SUPPRESSION; CHILD; COHORT ANALYSIS; CROHN DISEASE; DESCRIPTIVE RESEARCH; DRUG EFFICACY; DRUG FEVER; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALAISE; MALE; PANCREATITIS; PRIORITY JOURNAL; REMISSION; RETROSPECTIVE STUDY; RISK; SCHOOL CHILD; STATISTICAL ANALYSIS; TREATMENT FAILURE; ULCERATIVE COLITIS;

6-MERCAPTOPURINE; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; AZATHIOPRINE; CHILD; COHORT STUDIES; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS; YOUNG ADULT;

EID: 77956281034     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21221     Document Type: Article

References (44)

1. Travis SP, Stange EF, Lemann M, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut. 2006;55(suppl 1):i16-i35.
2. Lichtenstein GR, Abreu MT, Cohen R, et al. American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology. 2006;130:935-939. (Pubitemid 43374542)
3. de Boer NK, Van Bodegraven AA, Jharap B, et al. Drug insight: pharmacology and toxicity of thiopurine therapy in patients with IBD. Nat Clin Pract Gastroenterol Hepatol. 2007;4:686-694. (Pubitemid 350199222)
4. Present DH, Korelitz BI, Wisch N, et al. Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med. 1980;302:981-987. (Pubitemid 10125406)
5. Sandborn W, Sutherland L, Pearson D, et al. Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease. Cochrane Database Syst Rev. 2000;CD000545.
6. Timmer A, McDonald JW, Macdonald JK. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2007;CD000478.
7. Bebb JR, Scott BB. How effective are the usual treatments for ulcerative colitis? Aliment Pharmacol Ther. 2004;20:143-149.
8. Pearson DC, May GR, Fick GH, et al. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med. 1995;123: 132-142.
9. Dubinsky MC, Yang H, Hassard PV, et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology. 2002;122:904-915. (Pubitemid 34267273)
10. Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut. 2002;50:485-489. (Pubitemid 34638866)
11. de Jong DJ, Derijks LJ, Naber AH, et al. Safety of thiopurines in the treatment of inflammatory bowel disease. Scand J Gastroenterol Suppl. 2003;69-72. (Pubitemid 38112918)
12. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl. 1989;170:2-6.
13. Travis SP, Stange EF, Lemann M. European evidence-based consensus on the management of ulcerative colitis: current management. J Crohns Colitis. 2008;2:24-62. (Pubitemid 351179488)
14. Satsangi J, Silverberg MS, Vermeire S, et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55:749-753. (Pubitemid 43764536)
15. Derijks LJ, Gilissen LP, Engels LG, et al. Pharmacokinetics of 6-mercaptopurine in patients with inflammatory bowel disease: implications for therapy. Ther Drug Monit. 2004;26:311-318. (Pubitemid 38703020)
16. Dervieux T, Meyer G, Barham R, et al. Liquid chromatography-tandem mass spectrometry analysis of erythrocyte thiopurine nucleotides and effect of thiopurine methyltransferase gene variants on these metabolites in patients receiving azathioprine/6-mercaptopurine therapy. Clin Chem. 2005;51:2074-2084. (Pubitemid 41532623)
17. de Graaf P, de Boer NK, Jharap B, et al. Stability of thiopurine metabolites: a potential analytical bias. Clin Chem. 2008;54:216-218. (Pubitemid 351182621)
18. Vermunt JK, van Ginkel JR, van der Ark LA, et al. Multiple imputation of categorical data using latent class analysis. Sociol Methodol. 2008;38:369-397.
19. Goodman LA. Exploratory latent structure analysis using both identifiable and unidentifiable models. Biometrika. 1974;61:215-231.
20. Lazarsfeld PF. The logical and mathematical foundation of latent structure analysis. In: Stouffer SA, Guttman L, Suchman EA, et al, editors. Measurement and prediction. Princeton, NJ: Princeton University Press; 1966:361-412.
21. Lazarsfeld PF. The interpretation and mathematical foundation of latent structure analysis. In: Stouffer SA, Guttman L, Suchman EA, et al, editors. Measurement and prediction. Princeton, NJ: Princeton University Press; 1966:413-472.
22. Little RJ, Rubin DB. Statistical analysis with missing data, 2nd ed. New York: John Wiley & Sons; 2002.
23. Schafer JL. Analysis of incomplete multivariate data. London: Chapman & Hall; 1997.
24. Vermunt JK, Magidson J. Latent Gold 4.5 (computer program). Belmont, MA: 2008.
25. Rubin DB. Multiple imputation for nonresponse in surveys. New York: John Wiley & Sons; 1987.
26. van Ginkel JR. Rules for multiple imputation - multidimensional estimates (computer program). 2006.
27. Statistical Package for the Social Sciences (computer program). Chicago: SPSS; 2008.
28. Lennard L, Singleton HJ. High-performance liquid chromatographic assay of the methyl and nucleotide metabolites of 6-mercaptopurine: quantitation of red blood cell 6-thioguanine nucleotide, 6-thioinosinic acid and 6-methylmercaptopurine metabolites in a single sample. J Chromatogr. 1992;583:83-90.
29. Shipkova M, Armstrong VW, Wieland E, et al. Differences in nucleotide hydrolysis contribute to the differences between erythrocyte 6-thioguanine nucleotide concentrations determined by two widely used methods. Clin Chem. 2003;49:260-268. (Pubitemid 36143448)
30. O'Donoghue DP, Dawson AM, Powell-Tuck J, et al. Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease. Lancet. 1978;2:955-957. (Pubitemid 9061740)
31. Candy S, Wright J, Gerber M, et al. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut. 1995;37: 674-678.
32. Pearson DC, May GR, Fick G, et al. Azathioprine for maintaining remission of Crohn's disease. Cochrane Database Syst Rev. 2000;CD000067.
33. Glazier KD, Palance AL, Griffel LH, et al. The ten-year single-center experience with 6-mercaptopurine in the treatment of inflammatory bowel disease. J Clin Gastroenterol. 2005;39:21-26. (Pubitemid 40041338)
34. Chebli JM, Gaburri PD, De Souza AF, et al. Long-term results with azathioprine therapy in patients with corticosteroid-dependent Crohn's disease: open-label prospective study. J Gastroenterol Hepatol. 2007; 22:268-274. (Pubitemid 46181359)
35. Saibeni S, Virgilio T, D'Inca R, et al. The use of thiopurines for the treatment of inflammatory bowel diseases in clinical practice. Dig Liver Dis. 2008;40:814-820.
36. Hawthorne AB, Logan RF, Hawkey CJ, et al. Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ. 1992;305:20-22.
37. Mantzaris GJ, Sfakianakis M, Archavlis E, et al. A prospective randomized observer-blind 2-year trial of azathioprine monotherapy versus azathioprine and olsalazine for the maintenance of remission of steroiddependent ulcerative colitis. Am J Gastroenterol. 2004;99:1122-1128. (Pubitemid 38917818)
38. Sood A, Midha V, Sood N, et al. Role of azathioprine in severe ulcerative colitis: one-year, placebo-controlled, randomized trial. Indian J Gastroenterol. 2000;19:14-16. (Pubitemid 30048938)
39. George J, Present DH, Pou R, et al. The long-term outcome of ulcerative colitis treated with 6-mercaptopurine. Am J Gastroenterol. 1996; 91:1711-1714.
40. Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology. 2000;118:705-713. (Pubitemid 30171620)
41. Cuffari C, Theoret Y, Latour S, et al. 6-Mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity. Gut. 1996;39: 401-406. (Pubitemid 26338529)
42. Kirschner BS. Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease. Gastroenterology. 1998; 115:813-821. (Pubitemid 28452927)
43. Andrews JM, Travis SP, Gibson PR, et al. Systemic review: does concurrent therapy with 5-ASA and immunomodulators in inflammatory bowel disease improve outcomes? Aliment Pharmacol Ther. 2009;29:459-469.
44. Campbell S, Ghosh S. Effective maintenance of inflammatory bowel disease remission by azathioprine does not require concurrent 5-aminosalicylate therapy. Eur J Gastroenterol Hepatol. 2001;13:1297-1301. (Pubitemid 33111974)